Evidence map›Paper›PMID 28735458›Full record

ArticleJournal of neuro-oncology2017

The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.

Iddo Paldor, Sara Abbadi, Nicolas Bonne, Xiaobu Ye, Fausto J Rodriguez, David Rowshanshad, MariaLisa Itzoe, Veronica Vigilar, Marco Giovannini, Henry Brem and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. An unusual finding of an anaplastic meningioma in NF2-related schwannomatosis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Iddo PaldorDepartments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sara AbbadiDepartments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nicolas BonneDepartment of Otology and Neurotology, University Hospital of Lille, and INSERM U1008, University of Lille, Lille, France.
Xiaobu YeDepartments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fausto J RodriguezDepartments of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David RowshanshadDepartments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
MariaLisa ItzoeDepartments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Veronica VigilarDepartments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Marco GiovanniniDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Henry BremDepartments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jaishri O BlakeleyDepartments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Betty M TylerDepartments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. btyler@jhmi.edu.ORCID http://orcid.org/0000-0001-9800-6969
Johns Hopkins University · USInserm · FRUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurofibromatosis type 2 (NF2), a neurogenetic condition manifest by peripheral nerve sheath tumors (PNST) throughout the neuroaxis for which there are no approved therapies. In vitro and in vivo studies presented here examine agents targeting signaling pathways, angiogenesis, and DNA repair mechanisms. In vitro dose response assays demonstrated potent activity of lapatinib and nilotinib against the mouse schwannoma SC4 (Nf2

Indexed as

AnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCell Line, TumorCell SurvivalChemoradiotherapyEverolimusLapatinibMiceMice, NudeMice, TransgenicModels, StatisticalNeoplasm TransplantationNeurilemmomaNeurofibromatosis 2Antineoplastic AgentsBevacizumabEverolimusLapatinibnilotinibPyrimidinesQuinazolinesLapatinibNilotinibPeripheral schwannomaRadiation

Identifiers

PMID28735458
OpenAlexW2739040131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.